VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PLUR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PLURPluri Inc.
$0.94$8M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. PLUR
  4. Financial Ratios

Pluri Inc. (PLUR) Financial Ratios

Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE N/A. (2002–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

PLUR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$8M$20M$31M$30M$29M$40M$111M$161M$77M$129M$112M
Enterprise Value$40M$52M$60M$53M$54M$59M$105M$154M$72M$120M$107M
P/E Ratio →-0.23——————————
P/S Ratio3.8520.0423.4892.91102.50169.21—6995.131418.072582.50—
P/B Ratio———5.591.921.231.952.873.514.533.70
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

PLUR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—50.9344.55162.93188.02250.54—6680.351342.032406.08—
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

PLUR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin44.6%44.6%49.0%98.8%96.9%-350.0%—-6726.1%96.3%96.0%—
Operating Margin-2454.5%-2454.5%-1659.9%-6796.9%-9493.4%-17774.8%—-128156.5%-65800.0%-67462.0%—
Net Profit Margin-2344.6%-2344.6%-1690.3%-6407.4%-9867.9%-17624.8%—-126747.8%-65383.3%-52252.0%—

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE——-992.7%-201.7%-119.3%-92.3%-88.1%-74.8%-140.3%-88.9%-81.3%
ROA-75.0%-75.0%-57.7%-46.3%-47.7%-51.0%-62.7%-60.2%-100.5%-68.3%-66.6%
ROIC-90.7%-90.7%-59.9%-48.8%-44.9%-61.3%-76.4%-66.4%-142.5%-111.9%-73.1%
ROCE——-107.1%-55.2%-51.2%-58.1%-72.5%-73.1%-132.7%-107.9%-77.5%

PLUR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity———5.471.950.890.430.03———
Debt / EBITDA———————————
Net Debt / Equity———4.221.600.59-0.12-0.13-0.19-0.31-0.16
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-26.25-26.25-25.64-23.65-33.27-45.64-638.29-147.73-1217.48-27.88—

PLUR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio0.270.270.686.987.378.465.856.073.233.755.36
Quick Ratio0.270.270.686.987.378.465.856.073.153.755.36
Cash Ratio0.240.240.646.737.158.065.645.802.913.504.82
Asset Turnover—0.040.030.010.010.00—0.000.000.00—
Inventory Turnover————————0.00——
Days Sales Outstanding—78.68197.25714.33670.232060.53—25550.009604.916183.10—

PLUR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$10M$6M$5M$5M$4M$4M$2M$2M$1M$1M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Speculative Valuation Amidst Operational Uncertainty

As reported in recent financial filings, Pluri's price-to-sales ratio of 13.67x suggests that the market is pricing the company as a high-growth platform rather than a clinical-stage biotech, despite the lack of consistent, recurring revenue streams to justify such a premium valuation relative to its peers.

The current valuation appears to rely heavily on the potential of the 3D bioreactor IP rather than tangible financial performance. Investors should monitor whether this multiple contracts as the market reconciles the company's pivot to CDMO services with its historical inability to generate sustainable commercial revenue.

Persistent Decay in Capital Efficiency

Based on reported figures, Pluri's ROIC has remained consistently negative, reaching -22.5% in 2026Q3, which indicates that the company is currently destroying shareholder capital rather than compounding it through its research and development activities or its recent strategic shift toward industrial manufacturing services.

The negative return on capital reflects the structural imbalance between heavy fixed-cost investments in Haifa-based facilities and the lack of corresponding commercial output. This trend suggests that the company's current capital allocation strategy may be unsustainable without a significant improvement in operational efficiency or a major breakthrough in revenue generation.

Working Capital Management Remains Erratic

According to recent quarterly data, Pluri's asset turnover ratio has stagnated at 0.01, highlighting a profound inability to convert its specialized manufacturing infrastructure into meaningful revenue, while the volatility in its cash conversion cycle suggests significant challenges in managing supplier and customer payment terms effectively.

The extremely low asset turnover ratio underscores the underutilization of the company's manufacturing assets. Investors should investigate whether the recent pivot to CDMO services can improve these metrics or if the current infrastructure remains a persistent drag on the company's overall operational efficiency.

Critical Liquidity Buffer Rapidly Depleting

As disclosed in recent SEC filings, Pluri's current ratio has plummeted to 0.33 as of 2026Q3, a sharp decline from historical levels, which indicates that the company's ability to meet its short-term obligations is severely compromised and suggests an urgent need for external capital to maintain operations.

The rapid deterioration of the liquidity position leaves little room for error regarding clinical trial timelines or operational disruptions. This vulnerability warrants close monitoring, as the company may be forced to pursue highly dilutive financing options to address its immediate cash requirements and sustain its ongoing research initiatives.

Misapplication of Revenue-Based Valuation Metrics

The most commonly misapplied ratio for Pluri is the price-to-sales multiple, which obscures the company's true economic reality by treating non-recurring grant income and milestone payments as sustainable commercial revenue, thereby failing to account for the high probability of future dilution and the lack of operational scale.

Analysts should instead focus on cash burn rates and the remaining runway, as these metrics provide a more accurate assessment of the company's survival prospects. Relying on P/S multiples in a pre-commercial biotech context often leads to an overestimation of value by ignoring the binary nature of clinical and regulatory outcomes.

Download Financial Ratios Data

Includes 30+ ratios · 25 years · Updated daily

Consensus & Technical Research Suite
Open PLUR Terminal

PLUR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PLUR — Frequently Asked Questions

Quick answers to the most common questions about buying PLUR stock.

What is Pluri Inc.'s P/E ratio?

Pluri Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.

Is PLUR stock overvalued?

Based on historical data, Pluri Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Pluri Inc.'s profit margins?

Pluri Inc. has 44.6% gross margin and -2454.5% operating margin.